NasdaqGS:DFTXPharmaceuticals
Did New Real‑World GAD Data Just Reframe Definium Therapeutics' (DFTX) Late‑Stage Pipeline Potential?
Earlier in July 2026, Definium Therapeutics reported results from a large U.S. healthcare claims study of over 1.27 million adults with generalized anxiety disorder, revealing frequent discontinuation, rapid switching, and prolonged gaps in pharmacologic treatment despite guideline recommendations.
The analysis, published in CNS Spectrums, highlights how limited innovation since 2007, fragmented treatment guidance, and common comorbid depression create a substantial unmet need for...